Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Praliciguat (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CAPACITY-HFpEF
  • Sponsors Akebia Therapeutics; Ironwood Pharmaceuticals

    • Most Recent Events

    • 20 Oct 2020 Results assessing efficacy and adverse effects of praliciguat in patients with Heart failure with preserved ejection fraction, published in the JAMA: the Journal of the American Medical Association.
    • 12 Jan 2020 Rationale and design published in the American Heart Journal
    • 30 Oct 2019 According to a Cyclerion Therapeutics Media release, company will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the topline results from the Phase 2 proof-of-concept studies of praliciguat.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top